A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma

NCT06586294 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

294

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Drug: AK129 Drug：oxaliplatin Drug：capecitabine
DRUG: Drug: AK129 Drug：cadonilimab Drug：oxaliplatin Drug：capecitabine

Sponsor

Akeso